Why Trump May Not be Big Pharma’s Saviour
The US pharmaceutical industry is scrambling to align with President Donald Trump’s policy agenda, but may not get all it wishes for… In its first few weeks in power,…
Patrick is the managing editor of PharmaBoardroom, writing and editing stories on all things healthcare and the life sciences. The holder of a Master's Degree in International Relations, Patrick has contributed to over 40 country reports and is a fluent Mandarin speaker.
The US pharmaceutical industry is scrambling to align with President Donald Trump’s policy agenda, but may not get all it wishes for… In its first few weeks in power,…
Since Paul Hudson took the helm in 2019, Sanofi has been in transformation mode, shedding its consumer health assets to focus on high-growth areas like oncology, immunology, and vaccines. With…
Santen is on a mission to reshape the future of eye health. With three major product launches ahead, bold biotech deals, and a revamped global strategy, the Japanese pharma is…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access. Even the most innovative drug is useless if patients…
Puerto Rico leads all US jurisdictions in biopharmaceutical exports, shipping to over 120 countries. With a rapidly expanding life sciences sector and growing pharma logistics capabilities, the island is positioning…
Extending not only lifespan, but “healthspan,” and ensuring people live healthier lives for longer is moving beyond purely clinical settings. Experts gathered last week at the Global Healthspan 2025 Summit…
Since Christopher Viehbacher took the reins of Biogen in 2022, he has launched a USD 1 billion cost-cutting and priority refocusing plan, made significant deals, and launched the firm’s Alzheimer’s…
Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease. As people live longer, the threat…
A wave of blockbuster biologics is set to lose patent protection, creating a major inflection point for the biosimilars market in 2025 and beyond. While Europe remains the global leader…
See our Cookie Privacy Policy Here
